Phase 1 Clinical Trial of Avasopasem in Patients with Metastatic Hormone Receptor Positive Breast Cancer with Progression on a CDK 4/6 Inhibitor and Hormonal Therapy (CTMS# 24-0096)
Lay Description
This is a single institution, non-randomized, phase 1 with a dose expansion clinical trial investigating the addition of a novel agent, Avasopasem (GC4419), in patients with hormonal receptor positive (HR+) metastatic breast cancer with progression while on treatment with a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor and an aromatase inhibitor.
Category
- Cancers and Other Neoplasms
- Breast
- IRB Number
- STUDY00000816
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- -
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Exclusion Criteria
Study Design
Study Contact
Regulatory Point of Contact
Frances Crawford
210-450-5037
crawfordf1@uthscsa.edu
Regulatory Point of Contact
Myrna Montenegro
210-450-5954
montenegro@uthscsa.edu
Regulatory Point of Contact
Benjamin Schleif
210-450-1366
schleifb@uthscsa.edu
Regulatory Point of Contact
Morgan Seekatz
210-450-1133
seekatz@uthscsa.edu
Principal Investigator
Kate Lathrop